Compare Stocks

Date Range: 

 Enlivex TherapeuticsTiziana Life SciencesSatsuma PharmaceuticalsCalithera BiosciencesObsEva
SymbolNASDAQ:ENLVNASDAQ:TLSANASDAQ:STSANASDAQ:CALANASDAQ:OBSV
Price Information
Current Price$9.57$2.36$4.94$1.98$2.56
52 Week RangeBuyBuyHoldBuyHold
MarketRank™
Overall Score1.41.21.51.81.4
Analysis Score3.53.52.13.43.2
Community Score3.42.32.42.82.3
Dividend Score0.00.00.00.00.0
Ownership Score0.00.01.71.70.8
Earnings & Valuation Score0.00.01.31.30.6
Analyst Ratings
Consensus RecommendationBuyBuyHoldBuyHold
Consensus Price Target$33.00$9.50$6.13$5.20$11.80
% Upside from Price Target244.83% upside302.54% upside23.99% upside162.63% upside360.94% upside
Trade Information
Market Cap$150.82 million$151.56 million$155.75 million$146.62 million$147.34 million
Beta1.141.411.451.770.99
Average Volume359,793893,936363,5751,421,7344,616,183
Sales & Book Value
Annual RevenueN/AN/AN/A$22.25 millionN/A
Price / SalesN/AN/AN/A6.59N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$1.09 per share($0.09) per share$6.64 per share$2.24 per share$1.01 per share
Price / BookN/AN/AN/A0.88N/A
Profitability
Net Income$-9,380,000.00$-9,320,000.00$-28,170,000.00$-89,860,000.00$-108,790,000.00
EPS($1.11)($0.03)($4.80)($1.90)($2.49)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)-34.60%N/A-46.33%-66.64%-256.23%
Return on Assets (ROA)-28.47%N/A-42.22%-56.60%-93.21%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.02%N/A0.02%N/A1.14%
Current Ratio7.23%1.86%11.70%7.07%2.06%
Quick Ratio7.23%N/A11.71%7.07%2.06%
Ownership Information
Institutional Ownership Percentage2.39%N/A56.37%73.99%52.74%
Insider Ownership PercentageN/AN/A45.65%11.90%N/A
Miscellaneous
Employees368189242
Shares Outstanding15.76 million64.22 million31.53 million74.05 million57.55 million
Next Earnings Date5/17/2021 (Estimated)6/16/2021 (Estimated)5/11/2021 (Estimated)8/9/2021 (Estimated)8/5/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableOptionableNot Optionable
SourceHeadline
Obseva SA (OBSV) has gained 4.29% Monday In Premarket Trading - InvestorsObserverObseva SA (OBSV) has gained 4.29% Monday In Premarket Trading - InvestorsObserver
investorsobserver.com - May 11 at 1:35 PM
ObsEva SA (NASDAQ:OBSV) Has Recovered 33.75% So Far, But Another 125% Gain Cannot Be Ruled OutObsEva SA (NASDAQ:OBSV) Has Recovered 33.75% So Far, But Another 125% Gain Cannot Be Ruled Out
marketingsentinel.com - May 9 at 7:17 PM
ObsEva (NASDAQ:OBSV) Releases  Earnings Results, Misses Expectations By $0.01 EPSObsEva (NASDAQ:OBSV) Releases Earnings Results, Misses Expectations By $0.01 EPS
americanbankingnews.com - May 7 at 3:14 PM
Appointments and advancements for May 6, 2021 | 2021-05-06 - BioWorld OnlineAppointments and advancements for May 6, 2021 | 2021-05-06 - BioWorld Online
bioworld.com - May 6 at 10:06 PM
ObsEva Announces First Quarter 2021 Financial Results and - GlobeNewswireObsEva Announces First Quarter 2021 Financial Results and - GlobeNewswire
globenewswire.com - May 6 at 3:04 AM
ObsEva appoints Clive Bertram as Chief Commercial Officer - GlobeNewswireObsEva appoints Clive Bertram as Chief Commercial Officer - GlobeNewswire
globenewswire.com - May 6 at 3:04 AM
Is Obseva SA (OBSV) a Leader in the Biotechnology Industry? - InvestorsObserverIs Obseva SA (OBSV) a Leader in the Biotechnology Industry? - InvestorsObserver
investorsobserver.com - May 4 at 1:35 PM
ObsEva SA (OBSV) Reports Complete Enrollment of Linzagolix Phase 3 EDELWEISS 3 Trial for Patients with Moderate to Severe Endometriosis-Associated Pain - StreetInsider.comObsEva SA (OBSV) Reports Complete Enrollment of Linzagolix Phase 3 EDELWEISS 3 Trial for Patients with Moderate to Severe Endometriosis-Associated Pain - StreetInsider.com
streetinsider.com - May 4 at 8:35 AM
ObsEva Announces Enrollment Completion of Linzagolix Phase 3 EDELWEISS 3 Trial for Patients with Moderate to Severe Endometriosis-Associated Pain - GlobeNewswireObsEva Announces Enrollment Completion of Linzagolix Phase 3 EDELWEISS 3 Trial for Patients with Moderate to Severe Endometriosis-Associated Pain - GlobeNewswire
globenewswire.com - May 4 at 8:35 AM
ObsEva Announces Enrollment Completion of Linzagolix Phase 3 EDELWEISS 3 Trial for Patients with Moderate to Severe Endometriosis-Associated PainObsEva Announces Enrollment Completion of Linzagolix Phase 3 EDELWEISS 3 Trial for Patients with Moderate to Severe Endometriosis-Associated Pain
finance.yahoo.com - May 4 at 8:35 AM
-$0.28 Earnings Per Share Expected for ObsEva SA (NASDAQ:OBSV) This Quarter-$0.28 Earnings Per Share Expected for ObsEva SA (NASDAQ:OBSV) This Quarter
americanbankingnews.com - May 3 at 4:36 AM
FinLab AG: Falk Schäfers and Matthias Kröner appointed to the Executive Board - Yahoo Finance UKFinLab AG: Falk Schäfers and Matthias Kröner appointed to the Executive Board - Yahoo Finance UK
uk.finance.yahoo.com - April 30 at 11:41 PM
ObsEva SA presents posters at the ACOG Annual Clinical and - GlobeNewswireObsEva SA presents posters at the ACOG Annual Clinical and - GlobeNewswire
globenewswire.com - April 30 at 6:40 PM
ObsEva SA presents posters at the ACOG Annual Clinical and Scientific Virtual Meeting April 30 - May 2, 2021ObsEva SA presents posters at the ACOG Annual Clinical and Scientific Virtual Meeting April 30 - May 2, 2021
finance.yahoo.com - April 30 at 6:40 PM
ObsEva SA (NASDAQ:OBSV): Can A Stock That’s Up 5.529% YTD Still Be Considered In Loss Territory?ObsEva SA (NASDAQ:OBSV): Can A Stock That’s Up 5.529% YTD Still Be Considered In Loss Territory?
marketingsentinel.com - April 29 at 3:49 PM
The Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout - BenzingaThe Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout - Benzinga
benzinga.com - April 28 at 12:58 AM
ObsEva SA (OBSV) Gets a Buy Rating from Wedbush - Smarter AnalystObsEva SA (OBSV) Gets a Buy Rating from Wedbush - Smarter Analyst
smarteranalyst.com - April 27 at 2:58 PM
ObsEva Starts Long-term Follow-Up Study To Evaluate Bone Mineral Density After Yselty Treatment - Yahoo FinanceObsEva Starts Long-term Follow-Up Study To Evaluate Bone Mineral Density After Yselty Treatment - Yahoo Finance
finance.yahoo.com - April 27 at 2:58 PM
ObsEva Starts Long-term Follow-Up Study To Evaluate Bone Mineral Density After Yselty TreatmentObsEva Starts Long-term Follow-Up Study To Evaluate Bone Mineral Density After Yselty Treatment
finance.yahoo.com - April 27 at 2:58 PM
ObsEva Starts Long-term Follow-Up Study To Evaluate Bone Mineral Density After Yselty Treatment - BenzingaObsEva Starts Long-term Follow-Up Study To Evaluate Bone Mineral Density After Yselty Treatment - Benzinga
benzinga.com - April 27 at 9:57 AM
ObsEva Initiates PRIMROSE 3 Bone Mineral Density Follow-Up Study in PRIMROSE 1 and PRIMROSE 2 Trial Participants - GlobeNewswireObsEva Initiates PRIMROSE 3 Bone Mineral Density Follow-Up Study in PRIMROSE 1 and PRIMROSE 2 Trial Participants - GlobeNewswire
globenewswire.com - April 27 at 9:57 AM
ObsEva Initiates PRIMROSE 3 Bone Mineral Density Follow-Up Study in PRIMROSE 1 and PRIMROSE 2 Trial ParticipantsObsEva Initiates PRIMROSE 3 Bone Mineral Density Follow-Up Study in PRIMROSE 1 and PRIMROSE 2 Trial Participants
finance.yahoo.com - April 27 at 9:56 AM
Thinking Of Buying ObsEva SA (NASDAQ:OBSV) Stock? Read This FirstThinking Of Buying ObsEva SA (NASDAQ:OBSV) Stock? Read This First
stocksregister.com - April 25 at 9:02 AM
Premature Labor Treatment Market to Witness Huge Growth by 2028 | AMAG Pharmaceuticals Inc, Kissei Pharmaceutical Co Ltd - Clark County BlogPremature Labor Treatment Market to Witness Huge Growth by 2028 | AMAG Pharmaceuticals Inc, Kissei Pharmaceutical Co Ltd - Clark County Blog
clarkcountyblog.com - April 24 at 8:53 AM
ObsEva Annual General Meeting 2021 Nasdaq:OBSV - GlobeNewswireObsEva Annual General Meeting 2021 Nasdaq:OBSV - GlobeNewswire
globenewswire.com - April 22 at 8:57 AM
DateCompanyBrokerageAction
3/2/2021Enlivex TherapeuticsHC WainwrightBoost Price Target
12/22/2020Tiziana Life SciencesB. RileyInitiated Coverage
9/10/2019Tiziana Life SciencesLaidlawSet Price Target
4/5/2021Satsuma PharmaceuticalsMizuhoBoost Price Target
3/8/2021Satsuma PharmaceuticalsCredit Suisse GroupUpgrade
9/11/2020Satsuma PharmaceuticalsSVB LeerinkDowngrade
1/5/2021Calithera BiosciencesCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellLower Price Target
1/5/2021Calithera BiosciencesSmith Barney CitigroupLower Price Target
6/2/2020Calithera BiosciencesWilliam BlairReiterated Rating
3/27/2020Calithera BiosciencesJefferies Financial GroupInitiated Coverage
1/12/2021ObsEvaWedbushReiterated Rating
11/9/2020ObsEvaJPMorgan Chase & Co.Downgrade
7/6/2020ObsEvaBMO Capital MarketsDowngrade
12/10/2019ObsEvaRoyal Bank of CanadaBoost Price Target
(Data available from 5/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.